• English
  • 简体中文
Login Register
Current Location: Home > Marketing Drugs(EU) Feedback Help
EMA Approvals
-
HMA Approvals
-

EMA:Drugs approved by European Medicines Agency through centralized Procedure. 

HMA:Drugs approved by EU members through Mutual Recognition Procedure.

For more information check in official website of members:

Drug label information in UK

Public Assessment Reports in UK

Marketed drugs in France

Marketed drugs in Italy

Marketed drugs in Switzerland

Marketed drugs in Sweden

Marketed drugs in Germany

Click here for more information

Brand name Nonproprietary Name Authorization date Marketing authorisation holder
Truvada emtricitabine, tenofovir disoproxil 2005-02-21 Gilead Sciences Ireland UC
Incresync alogliptin, pioglitazone 2013-09-20 Takeda Pharma A/S
Vipidia alogliptin benzoate 2013-09-19 Takeda Pharma A/S
Ivozall clofarabine 2019-11-15 ORPHELIA Pharma SAS
Fycompa perampanel 2012-07-24 Eisai GmbH
Keytruda pembrolizumab 2015-07-18 Merck Sharp & Dohme B.V.
Alli (previously Orlistat GSK) orlistat 2007-07-23 GlaxoSmithKline (Ireland) Limited
Repatha evolocumab 2015-07-18 Amgen Europe B.V.
Vaxzevria (previously COVID-19 Vaccine AstraZeneca) COVID-19 Vaccine (ChAdOx1-S [recombinant]) 2021-01-30 AstraZeneca AB
Levetiracetam Teva levetiracetam 2011-08-26 Teva B.V.
Amyvid florbetapir (18F) 2013-01-15 Eli Lilly Nederland B.V.
Matever levetiracetam 2011-10-04 Pharmathen S.A.
Pioglitazone Teva Pharma pioglitazone 2012-03-27 Teva Pharma B.V.
Lenalidomide Mylan lenalidomide 2020-12-19 Mylan Ireland Limited
Zelboraf vemurafenib 2012-02-18 Roche Registration GmbH
Epclusa sofosbuvir, velpatasvir 2016-07-07 Gilead Sciences Ireland UC
Xaluprine (previously Mercaptopurine Nova Laboratories) mercaptopurine 2012-03-10 Nova Laboratories Ireland Limited
Amglidia glibenclamide 2018-05-25 Ammtek
Hulio adalimumab 2018-09-17 Mylan S.A.S.
Comirnaty COVID-19 mRNA vaccine (nucleoside-modified) 2020-12-22 BioNTech Manufacturing GmbH